2nd Quarter - Report

SOCIETY FOR MATERNAL-FETAL MEDICINE for SOCIETY FOR MATERNAL-FETAL MEDICINE

Firm
Client
Income
—
Expenses
$20,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 916/HR 1897 MOMMA's Act (maternal mortality); S. 116 MOMS Act (maternal health); HR 2902/ S 1600 Maternal CARE Act; HR 1551/S 1960 Quality Care for Moms and Babies Act; maternal mortality, severe maternal morbidity, research in pregnancy

LobbyistCovered position, as disclosed
KATHRYN SCHUBERT —

Contacted: Food & Drug Administration (FDA); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 916 (116th), S. 116 (116th), H.R. 2902 (116th), H.R. 1551 (116th), H.R. 1897 (116th)

Budget/Appropriations BUD

FY20 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA

LobbyistCovered position, as disclosed
KATHRYN SCHUBERT —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); SENATE; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.